Clinical Trial Update: Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing intramyocardial delivery of autologous CD34+ stem cells for improving exercise capacity in subjects with refractory angina due to chro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angina Pectoris
• Myocardial Ischemia

Drugs mentioned

• Autologous CD34+ stem cells (CD34+ stem cells)

Snippet

Sponsor: Lisata Therapeutics, Inc. | Conditions: Chronic Myocardial Ischemia, Refractory Angina Pectoris | Phase 3 | Status: COMPLETED | Results posted: 2017-02-15